Her2 Antibodies Market - Emerging Trends and New Technologies Research 2015 - 2023

Her2 Antibodies Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023

Human epidermal growth factor receptor 2 (Her2) is an oncogene whose amplification or over-expression is observed to be associated with an aggressive type of breast cancer. Patients with amplified Her2 receptors are identified by tests such as Immunohistochemistry (IHC) and Fluorescent In-Situ Hybridization (FISH). According to the American Cancer Society, approximately 15% - 30% of breast cancers over-express the Her2 gene, whereas the Breast Cancer Society of Canada estimates the prevalence to be approximately 25%.

Download Exclusive Sample of this Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=7301

The global Her2 antibodies market is analyzed based on the type of treatment drugs which includes tratuzumab (Herceptin), lapatinib (Tykerb), Ado-trastuzumab emtansine (TDM-1, Kadcyla), Pertuzumab (Perjeta) and Everolimus (Afinitor). Tratuzumab (Herceptin) is the most widely prescribed drug for Her2 breast cancer. Tratuzumab is a targeted drug therapy attaching directly to the Her2 protein and slowing the growth of cancer cells. 

Expiry of its European patent in July 28, 2014, led to the advent of biosimilars primarily launched by Hospira, Inc. Roche still holds patent in the U.S. market till 2019 which will continue infusing revenue for the company until its new drugs Ado-trastuzumab emtansine (TDM-1, Kadcyla) and Pertuzumab (Perjeta) gains substantial share in the global Her2 antibodies market. Kadcyla is the first U.S. FDA approved antibody-drug conjugate for the treatment of HER2-positive metastatic breast cancer (mBC). Genentech has submitted a marketing authorization application for Kadcyla in various countries including Europe. Approval of this drug would improve the effectiveness of the therapy and lead to market growth during the forecast period.

The global Her2 antibodies market is also analyzed based on geography – North America, Europe, Asia Pacific and Rest of the World. North America dominates the global Her2 antibodies as the prevalence of breast cancer is high in this region coupled with higher patient affordability and the wide presence of insurance coverage. This attracts market players to primarily market their product in U.S. The market in developed regions is expected to grow further with introduction of novel drugs and the advent of biosimilars which will cater the demand of poor patients deprived of the treatment due to lack of insurance coverage and poor economic condition. The Asia Pacific and Rest of the World market would be driven by regulatory support and increasing demand for chemotherapy of breast cancer with rising prevalence of the disease in this region.

The growth of global Her2 antibodies market will be fueled by increasing incidence of breast cancer coupled with rising investment and support from the cancer associations. The American Cancer Society estimates that in 2014, about 232,670 of new cases of breast cancer would be diagnosed in the U.S. and about 40,000 women are expected to die from this cancer this year. Moreover, it estimates that currently there are 2.8 million women surviving with breast cancer in the U.S. In order to decrease the mortality rate of breast cancer, the American Cancer Society has granted more than 200 breast cancer research grants with USD 114 million of funding for research activities.

The Breast Cancer Society of Canada estimates diagnosis of 24,400 women with breast cancer in Canada and 5,000 women would die because of breast cancer in 2014. Such high mortality rate stimulates the need for effective therapy for patients at an economic cost. This would fuel increase in investment by various market players to capitalize on the available market opportunity. Some of the key market players present in the global Her2 antibodies market include Genentech Inc., Hospira, Inc., Epirus Biopharmaceuticals, Avesthagen Pharma, Celltrion, Inc., Biocon Limited and Mylan Pharmaceuticals.